Skip to content

Clinical Evaluation of Platelet Rich Fibrin Versus Subepithelial Connective Tissue Graft for Soft Tissue Augmentation

Clinical Evaluation of Platelet Rich Fibrin Versus Subepithelial Connective Tissue Graft for Soft Tissue Augmentation Around Implant in the Aesthetic Zone: A Randomized Control Clinical Trial

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03219944
Enrollment
16
Registered
2017-07-18
Start date
2017-08-15
Completion date
2018-01-01
Last updated
2017-07-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patients With at Least Single Missing Anterior Tooth, Thin Gingival Biotype

Brief summary

Soft tissue biotype is a critical factor for success of implant in the esthetic zone . Different soft tissue augmentation techniques have been employed to increase soft tissue thickness such as: autogenous grafts, allografts, xenografts and living cellular construct (LCC). Studies showed that, allografts and xenografts were inferior when compared with autogenous graft . However, few studies were conducted to evaluate the efficacy of soft tissue augmentation with platelet rich fibrin in order to overcome the patient morbidity with SCTG.

Interventions

PROCEDUREPlatelet Rich Fibrin

: Platelet Rich Fibrin for soft tissue augmentation around implant in the aesthetic zone

sub epithelial connective tissue graft for soft tissue augmentation around implant in the aesthetic zone

Sponsors

Cairo University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
20 Years to 60 Years
Healthy volunteers
Yes

Inclusion criteria

1. Patients with missing maxillary anterior toot teeth. 2. Thin gingival biotype. 3. Adequate inter-arch space for placement of the implant prosthetic part. 4. Good oral hygiene where gingival index is (0, 1) (Loe and Silness 1963).

Exclusion criteria

1. Patient with medical condition that is contraindicated with the surgical procedure 2. Patients receiving treatment that affect the healing ability. 3. Patients with local pathological defects related to the area of interest. 4. Smokers or pregnant women. 5. Patients with parafunctional habits that may jeopardize the implant longevity and affect the results of the study.

Design outcomes

Primary

MeasureTime frameDescription
Crestal bone resorption6 monthsmeasured mesially and distally using periapical xray in mm

Countries

Egypt

Contacts

Primary Contactmay mo kamal
maykamalmo@gmail.com01063392983

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026